Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Millipore Expands its EMPROVE® Raw Materials Portfolio to 400 Products

Published: Friday, January 31, 2014
Last Updated: Thursday, January 30, 2014
Bookmark and Share
Portfolio now includes 400 active pharmaceutical ingredients, excipients and biopharmaceutical materials.

Merck Millipore has announced the expansion of its EMPROVE® raw materials portfolio to 400 active pharmaceutical ingredients, excipients and biopharmaceutical materials.

The products offer comprehensive application-specific documentation in addition to superior quality, allowing pharmaceutical manufacturers to reduce qualification costs and accelerate time-to-market processes.

The portfolio includes EMPROVE® api for active pharmaceutical ingredients, EMPROVE® exp for excipients and EMPROVE® bio for biopharmaceutical materials - all of which provide the documentation needed to improve transparency and more efficiently receive necessary approvals.

The ready-to-use documentation, prepared in an internationally accepted format, prevents the errors that can result from gathering the information manually, minimizing risk to patients. The pre-compiled information also helps streamline the pharmaceutical process by saving both time and money.

Depending on the application, the EMPROVE® documentation can contain information such as manufacturer and manufacturing process details, testing procedures, purity and stability data. The active pharmaceutical ingredients are manufactured according to cGMP guideline ICH Q7, the excipients are EXCiPACT™ certified and the biopharmaceutical materials can be used in both upstream and downstream process steps.

"We are proud to reach the milestone of offering 400 different EMPROVE® raw materials to our customers," said Dr. Matthias Bucerius, Head of Pharma Raw Materials. "This product line has a long-standing history of combining reliability and safety with our deep knowledge of the pharmaceutical industry's ever-changing regulatory requirements, supporting our efforts to help our customers to secure final approvals more efficiently."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Enters Into Strategic Alliance with Turgut Ilaç
Company to provide Provantage® End-to-End solution for development and manufacture of biosimilars.
Friday, October 23, 2015
Merck Millipore Announces Agreement with Precision Biologics
Merck Millipore services include design and development of cost-effective process to deliver high yield and productivity.
Thursday, February 05, 2015
Merck Millipore Expands Biomanufacturing Sciences and Training Center in Japan
Facility expansion and relocation of existing operations from Yokohama, Kanagawa Prefecture to Tokyo.
Thursday, August 28, 2014
Merck Millipore Invests €12M in France Facility
The investments will expand ready-to-use media manufacturing at company's Molshiem facility.
Tuesday, August 12, 2014
Merck Millipore Announces Incoming CEO and President
Udit Batra, Ph.D. will be responsible for the organization’s strategic direction to drive growth and product innovation as well as oversight of the worldwide operations.
Tuesday, April 15, 2014
Merck Millipore Announces Co-marketing Agreement with groninger
Offering combines industry-leading single-use assemblies, sterility assurance solutions and stainless steel filling equipment.
Tuesday, August 13, 2013
Merck KGaA Passes EXCiPACT Audit for Certification as Provider of Pharmaceutical Excipients
Ensures current GMP and GDP requirements applied to pharmaceutical excipients through a recognized auditing and certification process.
Friday, August 02, 2013
Merck Millipore Announces Opening of its GMP Bioproduction Facility in France
Enables accelerated process development and production of proteins/monoclonal antibodies.
Friday, September 21, 2012
Merck Millipore Announces Exclusive Agreement with Julphar Diabetes
Collaboration to offer non-animal origin, recombinant human insulin as cell culture media supplement.
Wednesday, August 08, 2012
Andrew Bulpin to Assume Leadership of Process Solutions at Merck Millipore
Bulpin appointed as head of the company's process solutions business unit.
Wednesday, May 02, 2012
Merck Millipore and CCRM Collaborate to Optimize Conditions for Large-scale Stem Cell Cultivation
Collaboration to deliver optimized methodologies for cultivation of stem cells on microcarriers in Mobius® CellReady bioreactor systems.
Tuesday, March 13, 2012
Scientific News
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!